Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2005 results about "Interleukin" patented technology

Interleukins (ILs) are a group of cytokines (secreted proteins and signal molecules) that were first seen to be expressed by white blood cells (leukocytes). ILs can be divided into four major groups based on distinguishing structural features. However, their amino acid sequence similarity is rather weak (typically 15–25% identity). The human genome encodes more than 50 interleukins and related proteins.

Nanobody Targeting Human Serum Albumin and Its Application

The present invention discloses a human serum albumin-targeting nanobody and its application. A variety of human serum albumin-targeting nanobodies that can be used to construct long-acting fusion protein drugs and their immune screening methods are disclosed. The antibody is composed only of the heavy chain variable region and can be fused and expressed with therapeutic proteins or polypeptide drugs such as interleukin, interferon, and tumor necrosis factor in an Escherichia coli expression system. The fusion protein has the activity of specifically binding to human serum albumin, has a relatively high affinity, can effectively extend the drug half-life, and does not affect the biological activity of the recombinant protein drug at the same time.
Owner:CHANGCHUN INST OF BIOLOGICAL PRODS

Salt forms of IRAK4 degraders

PCT designated stage expiredWO2025080300A1AntipyreticAnalgesicsDiseaseReceptor
The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and / or degradation and uses of the same in the treatment various diseases.
Owner:KYMERA THERAPEUTICS INC

Probiotic with depression improving effect and microecological preparation and application thereof

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.
Owner:NINGBO UNIV

Preparation method and application of Lactobacillus paracasei IOB413 metagenic powder

The invention provides a preparation method and application of casei paracasei IOB413 after-generation powder, and relates to the field of microorganisms. Tartary buckwheat is used as a solid-state fermentation culture medium, and the lactobacillus paracasei IOB413 is fermented and then crushed to prepare the lactobacillus paracasei IOB413 after-generation powder with high flavone content. The flavonoid content of the metagenic powder prepared by the method is far higher than that in tartary buckwheat and casei paracasei IOB413, the levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL-6) can be reduced, the level of anti-inflammatory factor interleukin (IL-10) can be increased, the gingival index and the dental plaque index can be reduced, the growth of streptococcus mutans can be inhibited to a certain extent, and the metagenic powder can be used for preventing and treating the dental plaque. The oral micro-ecology is improved.
Owner:TIANJIN INNOORIGIN BIOLOGICAL TECH CO LTD +1

Anti-interleukin-6 antibody, and reagent and kit for detecting interleukin-6

The invention discloses an anti-interleukin-6 antibody or a reagent and a kit for detecting interleukin-6, and relates to the field of antibodies. The anti-interleukin-6 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of interleukin-6, and has good affinity or activity.
Owner:DONGGUAN PENGZHI BIOTECH CO LTD

Methods of using cyclic peptides for trapping interleukin-1 beta

Provided are methods of using a compound that binds to interleukin- 1 beta (IL- 1β) at a binding pocket of IL- 1β identified herein, which traps the IL- 1β and inhibits its interaction with interleukin- 1 receptor type I (IL-1R1).
Owner:MERCK SHARP & DOHME LLC

Il-18 fusion proteins and methods of producing il-18

Fusion proteins are provided that consist of essential elements such as one or more proteins / polypeptides capable of transporting into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. The proteins / polypeptides capable of transporting into the ER include, but are not limited to, immune globular proteins (e.g., Fc regions, VHH antibodies, and scFv), and globular proteins (e.g., serum albumin). In some embodiments, the IL-18 may be a pro-IL-18 similar to a natural precursor cytokine, wherein IL-18 is fused to the C-terminus of a propeptide or a propeptide variant thereof. In some embodiments, the fusion protein may further comprise a cleavable peptide linker.
Owner:FUSE BIOTHERAPEUTICS INC

Culture medium and culture method for persistent DC-CIK cells and application of culture medium and culture method

The invention relates to a culture medium and a culture method of persistent DC-CIK cells and application of the culture medium and the culture method, and belongs to the technical field of cell culture. The invention provides a culture medium for persistent DC-CIK cells, which takes a serum-free culture medium as a solvent and comprises a recombinant human granulocyte macrophage colony stimulating factor, a recombinant human interleukin-12, a recombinant human tumor necrosis factor-alpha, a recombinant human interferon-gamma, L-cysteine, glutathione, ginseng polysaccharide and streptomycin sulfate. According to the culture medium and the culture method of the persistent DC-CIK cells, proliferation and growth of the DC-CIK cells can be promoted, and very high tumor killing activity of the DC-CIK cells can be maintained for a long time.
Owner:广东壹加再生医学研究院有限公司

Polypeptide with binding affinity to IL-6 (interleukin-6) and application thereof

The invention discloses a polypeptide with binding affinity to IL-6 (interleukin-6) and application of the polypeptide. The amino acid sequence of the polypeptide comprises one or more of the sequences as shown in SEQ ID NO.1-6. The polypeptide compatible with IL-6 is obtained through screening, the polypeptide can be specifically compatible with IL-6, IL-6 is enriched, then IL-6 is adsorbed at an inflammation infection part, more choices are provided for absorption and removal of inflammatory factors and treatment of diseases related to too high IL-6, and the polypeptide can be used for IL-6 detection and preparation of drugs for targeted combination of IL-6 or treatment of Il-6 related diseases.
Owner:ZHEJIANG UNIV

Mesenchymal stem cell preparation for promoting knee joint repair, preparation method and application

The invention provides a mesenchymal stem cell preparation for promoting knee joint repair as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading transforming growth factor-beta1 and interleukin-6 on chitosan microspheres, then preparing a chitosan-oxidized starch-carboxymethyl-beta-cyclodextrin bracket loaded with sustained release microspheres, loading luteolin and quercetin, carrying out mixed culture with mesenchymal stem cells, adding a traditional Chinese medicine extract, and carrying out freeze-drying to obtain the luteolin-quercetin-modified mesenchymal stem cells. The mesenchymal stem cell preparation for promoting knee joint repair is prepared. The preparation method of the carbon anode plate for fluorine preparation is simple, the generation of polarization of the carbon anode plate is prevented, and the carbon anode plate has the advantages of low porosity, low ash content, high mechanical strength, high volume density, obviously prolonged service life, low resistivity and the like, and has a wide application prospect.
Owner:BEIJING SINOMENIUM STEM CELL TECH RES INST CO LTD

High affinity human antibodies to human IL-4 receptor

The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.
Owner:REGENERON PHARMACEUTICALS INC

In vitro model of inflamed intestinal barrier

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Owner:UNIVERSITE DE FRANCHE COMTE

Application of burdock root polysaccharide in preparation of medicine for treating cognitive impairment

The invention discloses application of burdock root polysaccharide in preparation of a medicine for treating cognitive impairment, and belongs to the technical field of traditional Chinese medicines. Experiments prove that the burdock root polysaccharide can improve cognitive impairment and autonomous exploration ability of D-galactose induced cognitive impairment model mice, increase the activity of superoxide dismutase in serum of the mice, reduce the content of malondialdehyde, reduce the content of hippocampus interleukin-1beta and tumor necrosis factor-alpha in brains of the mice, and improve the cognitive impairment activity of the mice. According to the present invention, with the composition, the loss of the neuron in the hippocampal region of the cognitive impairment model mouse can be reduced so as to achieve the neuron protection effect, such that the good treatment effect on the cognitive impairment can be provided, and the new approach is provided for the development of the cognitive impairment-related drug.
Owner:DALIAN MEDICAL UNIVERSITY

Application of scylla antibacterial peptide Scin in preparation of anti-inflammatory composition and preparation method of scylla antibacterial peptide Scin

The invention discloses application of scylla serrata antibacterial peptide Scycin in preparation of an anti-inflammatory composition and a preparation method of the scylla serrata antibacterial peptide Scycin. The nucleotide sequence of the scylla serrata antibacterial peptide Scycin is shown as SEQ ID NO.01. The invention further discloses a preparation method of the scylla serrata antibacterial peptide Scycin. In an LPS (lipopolysaccharide)-induced RAW 264.7 macrophage inflammation model, the recombinant expression plasmid vector containing the scylla antibacterial peptide Scin remarkably inhibits an inflammation cascade reaction by down-regulating expression of proinflammatory factors such as TNF-alpha (tumor necrosis factor-alpha) and IL-6 (interleukin-6), the anti-inflammatory effect of the recombinant expression plasmid vector is equivalent to that of a mesalazine positive control group, and obvious cytotoxicity is not observed.
Owner:XIAMEN UNIV

Synthesis and use of novel proteolysis chimera compound targeting interleukin-1 receptor-associated kinase 4 (IRAK4)

The present invention relates to the technical field of chemical pharmacy, and in particular to a compound for degradation of a targeted interleukin-1 receptor-associated kinase 4 (IRAK4), and a pharmaceutically acceptable salt of the compound. The compound can be used for treating or preventing IRAK4-mediated immune diseases, inflammatory diseases, and cancers.
Owner:GAN & LEE PHARM CO LTD

Enzyme-linked immunosorbent assay kit for soluble IL-6 protein content detection

The invention discloses an enzyme-linked immunosorbent assay kit for detecting the content of soluble IL-6 (interleukin-6) protein. The enzyme-linked immunosorbent assay kit comprises two anti-human IL-6 monoclonal antibodies, namely, IL-6-1C7 and IL-6-2E11. The amino acid sequence of a heavy chain variable region of the IL-6-1C7 monoclonal antibody is SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the IL-6-1C7 monoclonal antibody is SEQ ID NO.2; the amino acid sequence of a heavy chain variable region of the IL-6-2E11 is SEQ ID NO.3, and the amino acid sequence of a light chain variable region of the IL-6-2E11 is SEQ ID NO.4. The enzyme linked immunosorbent assay kit provided by the invention can effectively detect the content of soluble IL-6, and detection by using the kit finds that serum of healthy people contains soluble IL-6 protein with a certain basic level, the content of soluble IL-6 in serum of patients with inflammatory and autoimmune diseases and the like is obviously increased and is related to clinical staging and pathology of the patients, so that the content of soluble IL-6 in serum of patients with inflammatory and autoimmune diseases is obviously reduced. The detection of the content of the soluble IL-6 in the body fluid of the inflammatory patient has clinical value.
Owner:MULTI SCI(LIANKE) BIOTECH CO LTD

Mesenchymal stem cell hair growth liquid and preparation method thereof

The invention relates to the technical field of biological products, and discloses a mesenchymal stem cell hair growth liquid and a preparation method thereof, and the mesenchymal stem cell hair growth liquid comprises the following components: hair follicle mesenchymal stem cells; a hair follicle mesenchymal stem cell exosome; growth factors: a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGFs), a keratinocyte growth factor (KGF-7) and interleukin-10 (IL-10); vitamins: vitamin E, vitamin B5, vitamin B2, vitamin B6, vitamin C and biotin; the plant extracts comprise a cacumen biotae extract, a polygonum multiflorum extract, a ginseng extract, a peppermint extract, a purslane extract and a rhodiola rosea extract; other active ingredients: tripeptide and digoxin; the auxiliary material is a hyaluronic acid-collagen peptide graft copolymer; and the balance of a phosphate buffer solution.
Owner:SHANDONG TAIHONG BIOTECHNOLOGY DEV CO LTD

A cell line for specific quantitative calibration of interleukin-7 activity and its application

The present invention provides a cell line for specific quantitative calibration of interleukin 7 (IL-7) activity and its application. Specifically, the present invention provides a construct, a vector, a host cell, a kit and its application and preparation method. The construct, the vector, the host cell and the kit of the present invention can be used to construct an IL-7 reporter cell for specific quantitative calibration of interleukin 7 (IL-7) activity, thereby achieving stable, highly accurate and highly sensitive quantitative detection of IL-7 activity, and providing accurate quality control means for the development of IL-7 related drugs.
Owner:NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO LTD

IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor, wherein the subject has a TET2 and / or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and / or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and / or DNMT3A, if it is determined that the subject has at least one TET2 and / or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1

Interleukin-22 fusion proteins, and their pharmaceutical compositions

Provided herein are a fusion protein comprising an interleukin-22 domain and an albumin binding domain, and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory disease.
Owner:ANWITA BIOSCIENCES INC

Interleukin-17A / F inhibitor as well as preparation method and application thereof

The invention belongs to the technical field of chemical drugs, provides an interleukin-17A / F inhibitor as well as a preparation method and application thereof, and particularly relates to a compound as shown in a general formula (I), or a racemate, an isomer or medicinal salt thereof, which is used for treating diseases such as psoriasis and arthritis as the IL-17A / F inhibitor.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Monoclonal antibody against interleukin-6 protein and use thereof

PCT designated stageWO2025175663A1Antibacterial agentsAntipyreticAntigenDisease
Disclosed in the present invention are a monoclonal antibody against an interleukin-6 protein and the use thereof. The present invention provides a nucleic acid molecule, a vector, a cell, a composition, a product, a bispecific antibody, a CAR, an antibody-drug conjugate and a pharmaceutical composition comprising an anti-IL-6 monoclonal antibody or an antigen-binding fragment thereof; and further provides the use of the monoclonal antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the vector, the cell, the composition and the product in the detection of IL-6 or a nucleic acid fragment encoding same, in the preparation of a product for detecting IL-6, in a pharmaceutical composition for preventing or treating diseases related to abnormal IL-6 expression, and in the preparation of a pharmaceutical composition for regulating the expression level or activity of IL-6.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Double-target chimeric antigen receptor co-expressing CD47 and IL-15, CAR-T cell and application of CAR-T cell

The invention discloses a double-target chimeric antigen receptor for co-expression of CD47 and IL-15, a CAR-T cell and application of the CAR-T cell, and belongs to the technical field of genetic engineering, the double-target chimeric antigen receptor comprises a single-chain antibody scFv-EGFRv III, a single-chain antibody scFv-VEGF, CD47 and IL-15; the nucleotide artificial sequence of the single-chain antibody scFv-EGFRv III is as shown in SEQ ID NO. 6; the nucleotide artificial sequence of the single-chain antibody scFv-VEGF is as shown in SEQ ID NO. 9. According to the application disclosed by the invention, by performing sequence optimization on targets EGFRvIII and VEGF, the anti-tumor effect of CAR-T cells in glioblastoma can be improved, and by integrating immune checkpoint molecules CD47 and interleukin-15, the immunosuppression function of a CD47-SIRP alpha signal channel can be locally exerted.
Owner:SHANGHAI XINGRUIYIDA BIOTECHNOLOGY CO LTD

Interleukin-18 variants and methods of use

The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).
Owner:YALE UNIVERSITY

Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.
Owner:SANOFI BIOTECH SAS +1

Anti-IL-8 monoclonal antibody as well as variable region sequence and application thereof

The invention belongs to the technical field of biology, provides an anti-IL-8 monoclonal antibody, a variable region sequence of the anti-IL-8 monoclonal antibody and application of the anti-IL-8 monoclonal antibody, and discloses a monoclonal antibody with neutralizing interleukin-8 (IL-8) biological activity and the variable region sequence of the monoclonal antibody. The preparation method comprises the following steps: by taking IL-8 as an immune source and a mouse as an immune object, carrying out immune injection on the mouse, taking the spleen of the immune mouse to prepare a suspension, and carrying out cell fusion on the suspension and myeloma cells to obtain a hybridoma cell strain capable of expressing the anti-IL-8 monoclonal antibody so as to prepare the anti-IL-8 monoclonal antibody; according to the invention, a variable region amino acid sequence of the anti-IL-8 monoclonal antibody is cloned at the same time; the anti-IL-8 monoclonal antibody disclosed by the invention can be specifically combined with IL-8, so that the anti-IL-8 monoclonal antibody can be used for treating diseases related to abnormal or excessive or out-of-control expression and secretion of the IL-8.
Owner:FUJIAN HANHONG BIOTECHNOLOGY CO LTD

Synthetic cytokine receptors

PCT designated stage expiredWO2025007073A2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyInterleukin-9 receptorWhite blood cell
Provided herein are synthetic cytokine receptors, wherein each synthetic cytokine receptor comprises an extracellular domain, a transmembrane domain, and an interleukin 9 receptor (IL-9R) intracellular domain. Also provided herein are engineered cells expressing one or more such synthetic cytokine receptors.
Owner:DISPATCH BIOTHERAPEUTICS INC

A cell line for specific quantitative calibration of interleukin-15 activity and its application

The present invention provides a cell line for specific quantitative calibration of interleukin 15 (IL-15) activity and its application. Specifically, the present invention provides a construct, a vector, a host cell, a kit and its application and preparation method. The construct, the vector, the host cell and the kit of the present invention can be used to construct an IL-15 reporter cell for specific quantitative calibration of interleukin 15 (IL-15) activity, thereby achieving stable, highly accurate and highly sensitive quantitative detection of IL-15 activity, and providing accurate quality control means for the development of IL-15 related drugs.
Owner:NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO LTD